CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancer.
  
  LEARNING OBJECTIVES

  • Evaluate available and emerging data documenting the efficacy and safety of anti-PD-1/PD-L1 antibody-based approaches as neoadjuvant, adjuvant or consolidation therapy for patients with nonmetastatic non-small cell lung cancer (NSCLC).
  • Acknowledge the FDA approval of adjuvant EGFR tyrosine kinase inhibitor (TKI) therapy for localized NSCLC with EGFR mutations, and identify patients for whom treatment with this approach would be warranted.
  • Review published and emerging research data documenting the efficacy of EGFR TKIs as monotherapy and in combination with chemotherapy for metastatic NSCLC with EGFR tumor mutations, and apply this information in the care of appropriately selected patients.
  • Assess the efficacy and safety of commercially available ALK inhibitors for patients with metastatic NSCLC with ALK rearrangements, and use this information to select these drugs as first- and later-line therapy.
  • Recollect other oncogenic pathways, such as ROS1, RET, MET, HER2 and KRAS, mediating the pathogenesis of NSCLC for unique patient subsets, and recall published data with commercially available and experimental agents exploiting these targets.
  • Consider recent therapeutic advances related to anti-PD-1/PD-L1 antibodies as monotherapy or in combination with other systemic therapies for metastatic NSCLC, and discern how these approaches can be employed in the management of this disease.
  • Develop a long-term care plan for patients with progressive NSCLC, considering exposure to prior systemic therapy, performance status and personal goals of treatment.
  • Design an optimal approach to the long-term clinical care of patients with small cell lung cancer, considering available clinical research findings and the implications of age, symptomatology and other clinical factors.
  • Reflect on investigational agents and strategies currently in testing for lung cancer, and as applicable, refer eligible patients for clinical trial participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Research To Practice designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.
  
  AMERICAN BOARD OF SURGERY (ABS) — CONTINOUS CERTIFICATION (CC)
  Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABS credit.
  
  Please note, this program has been specifically designed for the following ABS practice area: complex general surgical oncology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation located at ResearchToPractice.com/PostESMO23/Lung/Presentations/CME.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Aaron Lisberg, MD
  Thoracic Medical Oncology
  University of California, Los Angeles (UCLA)
  Los Angeles, California
  
  Advisory Committee and Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Daiichi Sankyo Inc, G1 Therapeutics Inc, IQVIA, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Leica Biosystems, Lilly, Molecular Axiom, MorphoSys, Novartis, Novocure Inc, Oncocyte, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi; Contracted Research: AstraZeneca Pharmaceuticals LP, Calithera Biosciences, Daiichi Sankyo Inc, Dracen Pharmaceuticals, Duality Biologics, eFFECTOR Therapeutics Inc, WindMIL Therapeutics; Steering Committees: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Duality Biologics; Nonrelevant Financial Relationship: LUNGevity Foundation, National Institutes of Health (NIH).
  
  Luis Paz-Ares, MD, PhD
  Chair of the Medical Oncology Department at the Hospital Universitario 12 de Octubre
  Associate Professor at the Universidad Complutense
  Head of the Lung Cancer Unit at the National Oncology Research Center
  Madrid, Spain
  
  Advisory Committee: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Daiichi Sankyo Inc, GSK, Janssen Biotech Inc, Lilly, Merck, Mirati Therapeutics Inc, MSD, Novartis, Pfizer Inc, PharmaMar, Roche Laboratories Inc, Sanofi, Servier Pharmaceuticals LLC, Takeda Pharmaceuticals USA Inc; Board of Directors: Altum Sequencing, STAb Therapeutics; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Lilly, Mirati Therapeutics Inc, MSD, PharmaMar, Sanofi.
  
  Zofia Piotrowska, MD, MHS
  Assistant Professor of Medicine
  Harvard Medical School
  Massachusetts General Hospital
  Boston, Massachusetts
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Daiichi Sankyo Inc, Janssen Biotech Inc, Lilly, Merck, Sanofi, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc; Consulting Agreements: Blueprint Medicines, Daiichi Sankyo Inc; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Cullinan Oncology, Daiichi Sankyo Inc, Janssen Biotech Inc, Novartis, Spectrum Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company; Travel Support: Janssen Biotech Inc.
  
  WEBINAR PARTICIPANT — David R Spigel, MD — Consulting Agreements (Paid to Institution): AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Lilly, Lyell Immunopharma, Monte Rosa Therapeutics, Novartis, Novocure Inc, Regeneron Pharmaceuticals Inc, Sanofi; Contracted Research (Paid to Institution): AbbVie Inc, Aeglea BioTherapeutics, Agios Pharmaceuticals Inc, Amgen Inc, AnHeart Therapeutics, Apollomics Inc, Arcus Biosciences, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, Ascendis Pharma, Asher Biotherapeutics, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BIND Therapeutics Inc, BioNTech SE, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Calithera Biosciences, Celgene Corporation, Celldex Therapeutics, Clovis Oncology, Cyteir Therapeutics, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology, Ellipses Pharma, EMD Serono Inc, Endeavor BioMedicines, Erasca, Evelo Biosciences Inc, Faeth Therapeutics, Foundation Medicine, FUJIFILM Pharmaceuticals USA Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Grail Inc, GSK, Hutchison MediPharma, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, ImmunoGen Inc, Incyte Corporation, Inspirna, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Janux Therapeutics, Jazz Pharmaceuticals Inc, Kronos Bio, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Lyell Immunopharma, MacroGenics Inc, Merck, Moderna, Molecular Partners, Monte Rosa Therapeutics, Nektar, Novartis, Novocure Inc, OncXerna Therapeutics Inc, Peloton Therapeutics Inc, a wholly-owned subsidiary of Merck & Co Inc, Pfizer Inc, PTC Therapeutics, PureTech Health, Razor Genomics, Repare Therapeutics, Seagen Inc, Shenzhen Chipscreen Biosciences Co Ltd, Stemline Therapeutics Inc, Strata Oncology, Synthekine, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tango Therapeutics, Tarveda Therapeutics, Tesaro, A GSK Company, Tizona Therapeutics Inc, Transgene, Verastem Inc, Zai Lab; Nonrelevant Financial Relationship: UT Southwestern Medical Center.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Lilly, and Regeneron Pharmaceuticals Inc.
  
  Release date: December 2023
  Expiration date: December 2024
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.